# An Open-Label Study Examining the Long-Term Safety of Exenatide Given Twice Daily to Patients With Type 2 Diabetes Mellitus

> **NCT01876849** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 275 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** exenatide

## Key facts

- **NCT ID:** NCT01876849
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-12
- **Primary completion:** 2008-07
- **Final completion:** 2008-07
- **Target enrollment:** 275 (ACTUAL)
- **Last updated:** 2015-02-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01876849

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01876849, "An Open-Label Study Examining the Long-Term Safety of Exenatide Given Twice Daily to Patients With Type 2 Diabetes Mellitus". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01876849. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*